Kayawake Hidenao, Sakanoue Ichiro, Tanaka Satona, Yutaka Yojiro, Nishino Yoshihiro, Matsumoto Akira, Ryo Taiki, Matsubara Taichi, Nakajima Daisuke, Date Hiroshi
Department of Thoracic Surgery, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Gen Thorac Cardiovasc Surg. 2025 Aug;73(8):609-615. doi: 10.1007/s11748-024-02109-8. Epub 2024 Dec 9.
Generally, HLA matching between donors and recipients is not performed in lung transplantation (LTx). Therefore, whether HLA mismatch between donors and recipients (D/R mismatch) influences postoperative outcomes after LTx remains uncertain. In this study, we investigated the influence of D/R mismatch on postoperative outcomes after cadaveric LTx (CLT).
A total of 140 CLT procedures were performed between 2012 and 2020. After excluding 5 recipients with preformed DSA and 1 recipient undergoing re-LTx, 134 recipients were enrolled in this retrospective study. The postoperative outcomes were compared between recipients with higher and lower D/R mismatches.
The median D/R mismatch (A/B/DR loci) was 4.0 (range, 1-6). When dividing these 134 recipients into two groups (H group [D/R mismatch ≥ 5, n = 57] and L group [D/R mismatch ≤ 4, n = 77]), there were no significant differences in the patient backgrounds. The lengths of hospital and intensive care unit stays were similar (p = 0.215 and p = 0.37, respectively). Although the overall survival was not significantly better in the H group than in the L group (p = 0.062), chronic lung allograft dysfunction-free survival was significantly better in the H group than in the L group (p = 0.027). Conversely, there was no significant difference in the cumulative incidence of de novo donor-specific anti-HLA antibodies (dnDSAs) between the two groups (p = 0.716).
No significant difference in dnDSA development was observed between patients with higher and lower D/R HLA mismatches. Given the favorable outcomes in the high HLA mismatch group, CLTs can be performed safely in recipients with high D/R HLA mismatches.
一般来说,肺移植(LTx)中不进行供体和受体之间的HLA配型。因此,供体与受体之间的HLA错配(D/R错配)是否会影响肺移植术后的结果仍不确定。在本研究中,我们调查了D/R错配对尸体肺移植(CLT)术后结果的影响。
2012年至2020年期间共进行了140例CLT手术。在排除5例有预存DSA的受者和1例接受再次肺移植的受者后,134例受者纳入本回顾性研究。比较了D/R错配程度较高和较低的受者的术后结果。
D/R错配(A/B/DR位点)的中位数为4.0(范围1 - 6)。将这134例受者分为两组(H组[D/R错配≥5,n = 57]和L组[D/R错配≤4,n = 77]),患者背景无显著差异。住院时间和重症监护病房停留时间相似(分别为p = 0.215和p = 0.37)。虽然H组的总体生存率并不显著高于L组(p = 0.062),但H组无慢性肺移植功能障碍的生存率显著高于L组(p = 0.027)。相反,两组之间新生供体特异性抗HLA抗体(dnDSA)的累积发生率无显著差异(p = 0.716)。
在D/R HLA错配程度较高和较低的患者之间,未观察到dnDSA产生有显著差异。鉴于高HLA错配组的良好结果,CLT可在D/R HLA错配程度高的受者中安全进行。